A Phase II Study of Second-Line SarCNU (NSC 364432) in Patients with Recurrent/Metastatic Colorectal Cancer.
Latest Information Update: 09 Apr 2020
At a glance
- Drugs NSC 364432 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Sep 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 11 Sep 2005 New trial record.